Cimerli Success Drives Strong H1 At Formycon
Company Anticipates Highest Revenue In Its History Over Subsequent Quarters
Formycon delivered a strong H1, as its Lucentis biosimilar made significant strides in the US market. The company now anticipates the highest revenue in its history for 2023.
You may also be interested in...
Formycon has announced a June 2024 FDA action date for its FYB203 proposed aflibercept biosimilar rival to Eylea, which is due to be marketed by Coherus in the US.
A third settlement has been struck allowing a Stelara biosimilar to hit the US market in 2025, with partners Fresenius and Formycon agreeing terms with Johnson & Johnson that offer a launch date slightly later than previous settlers.
Formycon and Athos have merged aspects of their biosimilar development activities as part of a long-term strategic partnership.